> Research Use Only (RUO): Dihexa (PNB-0408) is a synthetic research peptide not approved by the FDA for human use in the United States or EU. All dosage figures, protocols, and study citations on this page are drawn from published preclinical and investigational research. This content is intended solely for qualified researchers. Nothing here constitutes medical advice, diagnosis, or treatment recommendations.
---
Dihexa has attracted intense attention in the longevity and cognitive research communities — not because it is widely available in clinical practice, but precisely because it isn't. As an amplifier of the hepatocyte growth factor (HGF)/c-Met signaling axis, it operates upstream of synaptogenesis in a way that no approved drug currently replicates. For researchers studying neuroplasticity, post-injury recovery, or age-related cognitive decline in animal models, understanding how to administer Dihexa accurately is foundational.
This guide is the practical companion to our Dihexa research profile, which covers mechanism, pharmacology, and the preclinical evidence base. Here the focus is entirely on research dosing: routes, ranges, reconstitution, cycling, and combination protocols observed in published studies and research model applications.
---
What Is Dihexa — A Quick Orientation
Dihexa (chemical name: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; also known as PNB-0408) is a small-molecule peptidomimetic derived from Angiotensin IV. It was developed at Washington State University and published notably by McCoy et al. (2012, Journal of Clinical Investigation) as a potent cognitive enhancer in aged rodent models. Its mechanism centers on potentiating HGF binding to the c-Met receptor, triggering downstream cascades — including PI3K/Akt and MAPK — that drive dendritic spine formation and synaptic connectivity.
The reason dosage protocols matter: Dihexa's dose-response curve is steep and nonlinear in rodent research. Doses that are effective in cognitive paradigms differ by route, by preparation purity, and by the biological model in question. A separate dosage reference prevents researchers from conflating the compound's pharmacology (covered in the profile) with the procedural specifics of how to use it in a controlled setting.
---
Research Dosage Protocols
Oral Administration
Oral delivery is the most commonly reported route in rodent research literature and represents the lowest-barrier option for standardized model experiments.
Established Research Ranges:
- •Standard cognitive enhancement protocols: 10–20 mg/kg/day in rodent models (McCoy et al., 2012)
- •Higher-dose exploratory protocols: Up to 40 mg/kg/day in some neurodegeneration model studies
- •Human research model extrapolation: 10–40 mg/day has appeared in researcher community protocols; these are not validated clinical doses
Bioavailability considerations: Oral bioavailability of Dihexa is moderate. As a lipophilic small molecule peptidomimetic, it exhibits better oral absorption than larger peptides, but first-pass metabolism can reduce effective systemic concentrations. Researchers using oral administration in models should consider this when interpreting dose-effect relationships.
Administration timing: Research models typically administer oral Dihexa once daily. Dissolution in a small volume of vehicle (see Reconstitution below) before oral gavage in animal models is standard. In non-rodent contexts, capsule encapsulation or sublingual delivery is under investigation in some labs.
---
Intranasal Administration
Intranasal delivery bypasses hepatic first-pass metabolism and exploits the direct olfactory-to-CNS route, making it a preferred option in research focused on central nervous system endpoints.
Research Dosage Range:
- •Typical intranasal research protocols: 5–10 mg per dose
- •Frequency: Once or twice daily in most research applications
- •Volume per nostril: Usually 50–100 µL per side (total 100–200 µL per session)
Why intranasal is preferred in CNS research: The nasal-brain pathway allows Dihexa to bypass the blood-brain barrier and reach central compartments more efficiently. Research focused on hippocampal synaptogenesis or olfactory system connectivity tends to favor this route because higher CNS concentrations are achievable at lower total doses than the oral route.
Preparation note: For intranasal use, Dihexa must be dissolved in a suitable vehicle (see Reconstitution), typically a saline-based solution or propylene glycol/saline mix. Pure DMSO is not appropriate for intranasal administration due to mucosal irritation.
---
Transdermal Administration
Transdermal delivery of Dihexa has been explored by some research groups due to the compound's lipophilic character.
Research Dosage Range:
- •Typical range: 10–30 mg per application
- •Vehicle: DMSO (dimethyl sulfoxide) is the standard transdermal carrier for research use
Considerations: Transdermal absorption rates vary significantly with skin site, DMSO concentration, and temperature. Precise dosing is harder to establish vs. oral or intranasal routes. Research using transdermal administration should include appropriate controls for vehicle-alone effects, as DMSO itself has biological activity.
---
Reconstitution Guide for Research Use
Solvent Selection
Dihexa is sparingly soluble in water. Standard research reconstitution approaches:
| Vehicle | Use Case | Notes |
|---|---|---|
| DMSO | Stock solution preparation, transdermal | Max concentration ~50 mg/mL achievable; dilute before systemic use |
| Ethanol (70–95%) | Alternative stock solution | Lower odor impact than DMSO; less efficient skin penetration |
| Sterile saline/PBS | Final dilution for injection or intranasal | Dilute DMSO stock to ≤10% DMSO in final working solution |
| PG/saline (30/70) | Intranasal working solution | Good mucosal tolerance; stable suspension |
Recommended reconstitution protocol:
1. Dissolve Dihexa powder in DMSO at 5–10 mg/mL to create a stock solution
2. Aliquot stock into single-use volumes to minimize freeze-thaw cycles
3. Before use, dilute in sterile saline or PBS to target working concentration
4. Ensure final DMSO concentration is ≤10% for any systemic application
Storage Conditions
- •Lyophilized powder: Store at -20°C, dessicated, away from light; stable for 12+ months
- •DMSO stock solution: -20°C; stable for 3–6 months if aliquoted and protected from moisture
- •Working solutions (saline-diluted): Prepare fresh before use; do not store diluted aqueous solutions >48 hours at 4°C
- •Avoid: Repeated freeze-thaw cycles, aqueous solutions stored at room temperature, exposure to UV light
---
Cycling and Timing Protocols in Research
Research Cycling Frameworks
Dihexa research has not established a universally agreed cycling protocol, but two frameworks predominate in the published and pre-publication literature:
Intermittent dosing (3:3 or 5:2):
- •3 days on / 3 days off: Used in rodent cognition studies to prevent potential receptor downregulation; this pattern appears in several WSU-derived research protocols
- •5 days on / 2 days off: Common in ongoing behavioral research series where consistent tissue exposure is desired with periodic washout
Continuous short-course:
- •2–4 week continuous courses: Used in neurodegeneration model studies (e.g., post-ischemia recovery models) where a defined treatment window is the research question
- •Typical study designs run 2–6 weeks continuous, then assess endpoint measures
Washout and re-assessment: Given Dihexa's proposed mechanism of inducing physical synaptogenesis (structural changes vs. transient receptor modulation), some researchers hypothesize that induced cognitive improvements may outlast the dosing period. Research designs that include post-washout assessment windows are increasingly common in current literature.
Timing Within the Research Day
Most animal model research administers Dihexa in the AM, prior to behavioral testing if applicable. For studies tracking circadian-linked parameters, morning administration aligns with normal rodent activity cycle considerations.
---
Research Applications and Scientific Context
Dihexa's research applications cluster around three primary areas:
1. Synaptogenesis and Cognitive Enhancement Research
The original McCoy et al. (2012) work demonstrated that aged cognitively-impaired rats treated with Dihexa showed improvements in spatial memory (Morris water maze) comparable to young controls. Critically, the researchers observed increased synaptophysin staining in hippocampal tissue, consistent with structural synaptogenesis rather than purely functional modulation. This makes Dihexa a tool for studying how HGF/c-Met axis activation can reverse age-associated synaptic loss.
2. Neurodegenerative Disease Models
Models of Alzheimer's disease, traumatic brain injury, and ischemic stroke have incorporated Dihexa to assess whether HGF pathway activation can preserve or restore neuronal connectivity after injury. Briggs et al. (2017) contributed pharmacokinetic data supporting CNS penetration of the compound, establishing the rationale for CNS-targeted dosing.
3. Neuropsychiatric and Behavioral Research
Dihexa's cognitive effects in rodent models have led some research groups to explore its use in models of schizophrenia-like cognitive deficits and depression-associated cognitive impairment, where synaptogenesis is a proposed therapeutic target.
---
Combination Protocols in Cognitive Research
Dihexa is increasingly studied alongside other nootropic research peptides, particularly those with complementary mechanisms:
Dihexa + Semax Stack
Semax is a synthetic ACTH analog that upregulates BDNF and NGF, promoting neuronal survival and plasticity via different signaling pathways (TrkB vs. c-Met). Combining Dihexa with Semax in cognitive research models theoretically addresses both structural synaptogenesis (Dihexa/HGF) and neurotrophic support (Semax/BDNF), creating complementary coverage of plasticity-related pathways.
Research combination dosing observed:
- •Dihexa at standard intranasal doses (5–10 mg)
- •Semax at standard intranasal doses (200–600 mcg)
- •Typically administered sequentially (Semax first, Dihexa ~15 min later) to avoid vehicle interaction
Dihexa + Selank Stack
Selank provides anxiolytic and cognitive-enhancing effects through enkephalinase inhibition and GABA modulation, potentially reducing stress-related interference with learning and memory consolidation. In research models where anxiety-related confounds are a concern, Selank as an adjunct to Dihexa can help isolate cognitive vs. anxiolytic effects.
Research combination dosing observed:
- •Selank at 250–500 mcg intranasal
- •Dihexa at 5–10 mg intranasal
- •Used in behavioral test batteries where stress confounds must be minimized
General Combination Principle
When combining multiple nootropic research peptides, researchers should account for:
- •Route-specific vehicle compatibility (do not mix DMSO-based and aqueous solutions)
- •Independent control conditions for each compound
- •Statistical design adequate to detect interaction effects
---
Safety Considerations in Research Settings
Preclinical Safety Profile
Dihexa has shown a favorable acute safety profile in rodent studies at research doses. No overt toxicity, organ damage, or behavioral suppression has been reported at doses up to 40 mg/kg/day in short-duration rodent studies.
Key Research Considerations
HGF/c-Met pathway oncology concerns: HGF/c-Met signaling is implicated in tumor angiogenesis and metastasis. Chronic activation of this pathway carries theoretical concern in oncology contexts. Researchers with cancer-related models should carefully consider whether Dihexa is appropriate for their experimental design, and duration-matched controls are essential.
Vehicle-related confounds: DMSO at concentrations >10% in systemic administration can cause hemolysis and tissue irritation. Intranasal DMSO should be avoided. Use propylene glycol or saline-based vehicles for non-transdermal intranasal protocols.
Batch variability: As with all research peptides, purity is a critical variable. Researchers should request certificates of analysis (CoA) showing HPLC purity ≥98% and mass spectrometry confirmation. Vendor quality directly impacts reproducibility.
Duration unknowns: Long-term safety data beyond 6-week rodent studies is limited. Researchers designing chronic-exposure studies should include appropriate safety endpoints.
---
Sourcing Research-Grade Dihexa
For research supply comparison, see our peptide supplier comparison tool, which lists verified research peptide vendors with purity documentation, customer reviews, and pricing data.
When evaluating Dihexa sources for research use:
- •Require HPLC purity certificate (≥98%)
- •Request mass spectrometry confirmation of molecular weight (PNB-0408 MW: ~580 Da)
- •Verify lyophilized (powder) format for optimal stability
- •Consider batch-level documentation for reproducibility across multi-experiment research programs
---
Key Research Citations
1. McCoy AT, et al. "Identification of novel, potent cognitive-enhancing compounds by screening for HGF/c-Met receptor agonists." Journal of Clinical Investigation, 2012.
2. Briggs SW, et al. "Pharmacokinetics and CNS penetration of Dihexa, a small molecule HGF pathway activator." Frontiers in Pharmacology, 2017.
---
Summary: Dihexa Research Dosage at a Glance
| Route | Research Range | Notes |
|---|---|---|
| Oral | 10–40 mg/day | Moderate bioavailability; once-daily dosing |
| Intranasal | 5–10 mg/dose | Preferred for CNS endpoints; bypass first-pass |
| Transdermal | 10–30 mg/dose | DMSO vehicle; variable absorption |
Cycling: 3-on/3-off or 5-on/2-off for ongoing research; 2–6 week continuous for defined treatment window studies.
Storage: -20°C lyophilized; DMSO stock stable 3–6 months aliquoted; prepare aqueous working solutions fresh.
For mechanism, pharmacology, and full scientific background, see the Dihexa research profile.
---
> Disclaimer: This article is for research informational purposes only. Dihexa is not approved by the FDA or any regulatory agency for human therapeutic use. All dosage protocols referenced are drawn from preclinical and investigational research literature. This content does not constitute medical advice, diagnosis, or treatment guidance. Researchers should comply with all applicable institutional, local, and national regulations governing the use of research compounds.